自体细胞因子诱导的杀伤细胞治疗肺癌患者的临床疗效观察

doi:10.11904/j.issn.1002-3070.2015.04.011

Abstract

Abstract: Objective To evaluate the clinical effect of cytokine induced killer cellular immunotherapies(CIK)on the patients with advanced lung cancer.Methods Peripheral blood mononuclear cell from 32 cases of patients with advanced lung cancer were isolated.Cells were cultured in DMEM supplemented with IFN-γ,IL-2,anti-CD3 monoclonal antibody and other cytokines,and transfused back into the patients in several times after 15 days of culture.Subsequently,we observed the size of tumor,the change of immunologic function by CIK treatment,the status of clinical symptoms,and the toxic and side effect.The clinical curative effect was also evaluated.Results The symptoms in 32 patients who received CIK therapy were reduced,and the side effects were light.Immunophenotype analysis showed that CD3 / CD4 coexpression were found in 34.4% patients,CD3 / CD8 coexpression in 68.2%,and CD3 / CD56 co-expression in 13.7% patients.CT images about 15 days after CIK cell transfusion showed that pleural effusion were decreased.Clinical evaluation effective rate was 56.0%,and disease control rate(CR + PR + SD)was 84.3%.Conclusion CIK cell immunotherapies of cancer patients can improve immunologic function of cancer patients and inhibit tumor growth and relieve the clinical symptom of patients,and improve the quality of life.

Key words: CIK cells, Lung cancer, Cellular immune

CLC Number:

ZHANG Likun,CAO Fenglin. Effect of autologous cytokine induced killer cell therapy in patients with lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 342-346.

References

1 Walker S.Updates in non-small cell lung cancer[J].Clin J Oncol Nurs,2008,12(4):587-596.
2 Spira A,Ettinger DS.Multidisciplinary management of lung cancer[J].N Engl J Med,2004,350(4):379-392.
3 Patel S,Mehta-Damani A,Shu H,et al.An analysis of variability in the manufacturing of dexosomes:implications for development of an autologous therapy[J].Biotechnol Bioeng,2005,92(4):238-249.
4 Shi M,Zhang B,Tang ZR,et al.Autologous cytokine induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma[J].World J Gastroenterol,2004,10(4):1146-1151.
5 Zhang YS,Yuan FJ,Jia GF,et al.CIK cells from patientswith HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R[J].World J Gastroenterol,2005,22(11):3339-3345.
6 Kim HM,Lim J,Park SK,et al.Antitumor activity of cytokine-induced killer cells against human lung cancer[J].Int Immunopharmacol.2007,7(13):1802-1807.
7 Niu Q,Wang W,Li Y,et al.Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies[J].Int Immunopharmacol,2011,11(4):449-456.
8 Schmidt-Wolf IG,Lefterova P,Mehta BA,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,13(21):1673-1679.
9 Helms MW,Prescher JA,Cao YA,et al.IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy[J].Cancer Immunol Immunother,2010,59(9):1325-1334.
10 Yang Z,Zhang Q,Xu K,et al.Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model[J].PLoS One,2012,7:e44802.
11 Schmidt-Wolf IG,Lefterova P,Johnston V,et al.Propagation of large numbers of T cells with natural killer cell markers[J].Br J Haematol,1994,87(3):453-458.
12 Linn YC,Lau LC,Hui KM.Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts[J].Br J Haematol,2002,116(1):78-1186.
13 Linn YC,Hui KM.Cytokine-induced killer cells:NK-like T cells with cytotolytic specificity against leukemia[J].Leuk Lymphoma,2003,44(9):1457-1462.
14 Wu C,Jiang J,Shi L,et al.Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced nonsmall cell lung cancer[J].Anticancer Res,2008,28(6B):3997-4002.
15 Liu L,Zhang W,Qi X,et al.Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma[J].Clin Cancer Res,2012,18(6):1751-1759.
16 吕俊杰,陶秀娟.CIK治疗恶性肿瘤的基础与临床研究[J].实用肿瘤学杂志,2012,26(4):373-376.

[1]	ZHANG Jiawen,YU Yan,ZHANG Wei,CAO Jingyan,LUO Wen,SHANG Lihua. Serum metabolomics of small cell lung cancer patients based on UPLC-TOF/MS [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 200-205.
[2]	LIU Zhiqiang,CHU Yanjie,LIU Jing,WANG Yanbo. Atractylenolide I regulates proliferation and invasion of lung cancer A549 cells through the TLR4/MyD88 pathway [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 228-232.
[3]	ZHANG Yanqiu,HAN Ameng,LI Jinwang,GU Tao,FU Zhanzhao,MAO Yu,ZHANG Zijian,YANG Zhen. The preliminary study on clinical application of CRT+ARC technique in patients with locally advanced lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 256-260.
[4]	ZHAO Su, ZHENG Xiaoyu, ZHU Kaibin, BU Jianlong, XU Shidong. Effect of complete lung cancer resection on the balance of Th17/Treg in the peripheral blood of patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 142-148.
[5]	HU Zhihui, ZHANG Jing. Research progress in the prediction of SNP on radiation-induced lung injury [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 87-91.
[6]	MULALI Dina, HU Xin, TUOHAYI Jiazina. The application and prospect of telemedicine in lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 555-557.
[7]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[8]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.
[9]	ZHONG Xuelai, YANG Haili, WANG Guonian. Effects of different anesthesia methods on postoperative cognitive function in elderly patients with lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 432-436.
[10]	ZHU Xiaoyun, ZHANG Yaning, LIN Fei, MA Biping. Analysis of lung cancer incidence and mortality in Jinshan District of Shanghai from 2002 to 2013 [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 437-441.
[11]	CUI Xiaoyan,TU Qing,GAN Jianhui. Comparison between nalbuphine and oxycodone applied for patient controlled analgesia on postoperative immunological factor levels in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 309-314.
[12]	WEI Jing,TAO Yuanmeihui,FU Yingmei,ZHAO Jizi,ZHANG Wenli,ZHANG Fengmin. Research progress in the interaction between pulmonary tuberculosis and lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 340-343.
[13]	LEI Junhua, XU Guanhua, ZENG Jiangzheng, HUANG Fen, HE Zhihui, LU Yanda. Research on JAK3/STAT3 mechanism of non-small cell lung cancer NCI-H1975 cells treated with cryptotanshinone combined with cisplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 198-202.
[14]	WAN Jingxuan, LI Honghong, ZHOU Xiangxiang, Ma Lin. Analysis for risk factors of pulmonary thromboembolism in the stage Ⅳ of lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 214-244.
[15]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.

Effect of autologous cytokine induced killer cell therapy in patients with lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments